A detailed history of Jane Street Group, LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 39,566 shares of JANX stock, worth $2.15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,566
Previous 20,132 96.53%
Holding current value
$2.15 Million
Previous $757,000 118.89%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$35.12 - $64.78 $682,522 - $1.26 Million
19,434 Added 96.53%
39,566 $1.66 Million
Q1 2024

May 15, 2024

BUY
$7.93 - $49.75 $159,646 - $1 Million
20,132 New
20,132 $757,000
Q2 2023

Aug 14, 2023

BUY
$11.08 - $15.92 $165,479 - $237,765
14,935 New
14,935 $177,000
Q1 2022

May 17, 2022

SELL
$13.24 - $20.24 $208,477 - $318,699
-15,746 Closed
0 $0
Q4 2021

Feb 15, 2022

BUY
$15.44 - $27.32 $243,118 - $430,180
15,746 New
15,746 $311,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.27B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.